About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Letter to the Editor
The debate about psychologist prescribing continues.
J. J. Rodos, DO, DSc
Toward Safer Prescribing: History, Challenges, and Potential Solutions in Outpatient Medication Safety
Successful approaches to reducing errors will require system improvements rather than exhortations for prescribers to “try harder.”
Edmond S. Weisbart, MD, and Howard E. Greenberg, MD, MSE, MBA
The authors discuss the use of rosiglitazone (Avandia®) and pioglitazone (Actos®) for patients with type-2 diabetes.
Fadia T. Shaya, PhD, MPH, Stacy Calloway, PharmD Candidate, Antoine C. El Khoury, PhD, and Josette Tomety, PharmD Candidate
The new Medicare prescription drug plan encourages beneficiaries to select generic over branded products.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Mr. Alexander summarizes presentations on androgen-suppressing therapies for men with prostate cancer and the associated risk of osteoporosis, the use of bone scans in prostate cancer, and genetic mutations as markers for selecting pharmacotherapy.
Walter Alexander, MS
The authors discuss therapies for asthma, chronic obstructive pulmonary disease, pulmonary hypertension, and respiratory syncytial virus disease, as well as rimonabant as an aid in smoking cessation.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
David Nash, MD, MBA, describes a White Paper about the ongoing problem of variations in health care, published by the Alliance of Community Health Plans.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, discusses ways to prevent accidental overdoses of acetaminophen in children and how to guide parents and caregivers who administer this medication.
Matthew Grissinger, RPh, FASCP
“Authorized” Generics May Pose Unauthorized Problems: Government Worries about Potential Brand-Name Blocking Technique
Stephen Barlas explains some potential problems associated with “authorized” generic drugs, that is, new chemical equivalents of brand-name drugs that are going off their patents.
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
The authors review telithromycin (Ketek™) for the treatment of respiratory infections.
Amber Bell, PharmD Candidate, Marlon Honeywell, PharmD, Evans Branch III, PharmD, Patty Ghazvini, PharmD, Anya LeBron, PharmD, and Keylow King, PharmD